Trade Tarsus Pharmaceuticals, Inc. - TARS CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.32
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021596 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02160%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000626 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00063%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021596 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000626 %
  (-$0.01)

Key Stats

• Prev. Close: 83.07
• Open: 82.46
• 1-Year Change: 43.16%
• Day's Range: 82.03 - 91.17

Trade Tarsus Pharmaceuticals, Inc. - TARS

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Tarsus Pharmaceuticals Inc revenues increased from $0K to $56.7M. Net income applicable to common stockholders totaled $1M vs. loss of $15.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to $0.05.